###### Key questions

What is already known about this topic?
=======================================

-   Previous efforts to assess the economic value to society of surgical services in the developing world have used the human capital approach as well as the more holistic value of a statistical life approach but have been quite limited and have used extensive modelling of the surgical services.

What are the new findings?
==========================

-   The value of lost welfare and value of a statistical life approaches are robust methodologies to attempt to capture the economic value of health interventions.

-   Using robust methodology, on average each cleft lip and cleft palate repair was found to contribute to economic well-being at the individual level (US\$16.1--US\$42.3K) and at the aggregate level (US\$7.9--US\$20.7 billion over 11 years). It is speculated that the expense of the programme per disability-adjusted life year averted was US\$149.

Recommendations for policy
==========================

-   This study indicates that the expansion of surgical capacity in the developing world is of significant economic and health value and should be a priority in global health efforts.

Introduction {#s1}
============

The Lancet Commission on Global Surgery (LCoGS) highlighted the need for surgical services in the developing world.[@R1] [@R2] Previous studies have addressed that need[@R3] [@R4] and the economic impact of surgical diseases.[@R5] These studies have examined either the *economic loss* due to failure to meet surgical needs, or the *potential economic gain* when the need is incompletely addressed. The losses to society and to individuals because of lack of surgical care are immense; 4.8 billion people, over half of the global population, lack access to such care.[@R11] For those with access to care, 81 million people a year face catastrophic expenditure (defined as 10% of household or 40% of non-food expenditure) because of surgical conditions, with the preponderance of these costs being non-medical.[@R12] Analyses require defining the health problem, the intervention and the counterfactual in addition to modelling the relationship between health and macroeconomic outcomes.[@R13] This can be challenging and controversial. Cost-of-illness (COI) studies, which combine direct and indirect (ie, lost productivity) cost of a disease, are most prominent. Within COI studies, the valuation of lost productivity based on gross national income (GNI) or gross domestic product (GDP), termed the 'human capital approach', is prevalent. This method emphasises macroeconomic losses associated with poor health and consequent treatment and has been criticised due to the unclear economic meaning that results from applying per capita measures of economic output to lost health and productivity. This criticism results in part from the fact that GNI and GDP are not aggregate measures of individual economic productivity, and also there is typically no accounting for unemployment.[@R14]

The value of a statistical life (VSL), an economic concept that has been refined over the past half century, attempts to define a monetary value for changes in health risks. VSL estimates are derived by assessing how individuals value trade-offs between wealth and small changes in their mortality risk. VSL studies can be either survey-based, so-called 'stated preference' studies, or use a 'revealed preference' approach, relying on wage differentials of occupations with varying risk profiles.[@R15] This paper applies the value of lost welfare (VLW) approach to the work of a large non-governmental organisation (NGO) over an 11-year period, adopting the concept of VSL. It is intended to capture the total economic welfare (market and non-market) losses associated with disability or premature mortality, including the loss of utility due to lost leisure time and foregone consumption opportunities, along with less tangible losses such as those due to pain and suffering.

Smile Train (ST) is an international charity that in addition to training and resources provides financial support on a case-by-case basis to hospitals and surgeons in access-limited regions for the repair of cleft lip (CL) and cleft palate (CP). This programme has been previously evaluated in terms of averted burden of disease (BoD)[@R16] and the 'human capital' approach described above.[@R17] The current study uses the economic valuation methodology applied by the LCoGS to value this vertically oriented surgical intervention.

Methods {#s2}
=======

This study determined the clinical effect of the cleft surgery programme by first estimating the total disability-adjusted life years (DALYs) averted through the operative interventions, then determined the macroeconomic benefit of that work. Determining the counterfactual was challenging in that it is impossible to know how many of the patients would have been cared for in the absence of the programme. An attempt was made to identify what that proportion of our total may have been, based on anecdotal information from a time prior to the existence of ST. This endeavour, as could be expected, lacked quantitative rigour, and the findings were consistent with the authors\' own guesses of a maximum of about 10% of the cases carried out in this study. In developing countries, the relative lack of financial incentives without the programme contrasted with the 100% rate of reimbursement with it could be reasonably invoked as accounting for this change. We conducted the study first comparing health and economic benefits to a postulated counterfactual of no intervention, then calculated those benefits on the basis of only 90% of the patients receiving care because of the programme.

The ST global database for 2001--2011 provides the following anonymised data: age at operation, country and surgical intervention (CL or CP repair). This was the same database used for a previous study that applied a human capital approach to estimate economic benefit.[@R17] Country-specific and age-specific life expectancy estimates were obtained from the UN and WHO tables,[@R18] and GNI per capita values were taken from the World Bank data. We adjusted these GNI/capita figures for inflation to 2011 international dollars, prior to our making the calculations for the study. Economic benefit was calculated using the Purchasing Power Parity figures in order to avoid the variables of relative price differences between countries, and expressed in 2011 international dollars.[@R19]

Disability weights (DWs) for the untreated conditions of CL and CP were extracted from the Global Burden of Disease (GBD) study.[@R20] DALYs secondary to a disease are calculated by adding years of life lost (YLLs) and years lost to disability (YLDs). Given that we did not account for potential mortality, only YLDs were calculated for this study. We adopted an incidence perspective when calculating YLDs; consequently, we discounted their future value over the patient\'s remaining life at 3%. Residual postoperative DALYs were estimated by the method of McCord and Chowdhury[@R21] and used by others[@R22] in which allowance is made for failure of the intervention to resolve 100% of the disability. This method introduces a risk of permanent disability (RPD) if there is no intervention and an estimate of residual disability (ERD) following the intervention. For cleft deformities, the RPD is 1.0, as all individuals with these deformities will continue to suffer disability in the absence of intervention. We used an ERD of 0.8 for CL repair and 0.5 for CP repair, postulating that a CL repair roughly resolves 80% of the disability and a CP repair 50%. The averted DALYs were calculated by multiplying the age-specific, year-specific and country-specific years left to live at the age of operation by the DW and ERD for each patient.

We estimated the VSL and its annualised equivalent, the VSL-year (VSLY), for each country as described by Alkire *et al*.[@R10] The VSLY is taken to be the value of a DALY, and therefore our assessment of benefit multiplies total YLDs averted by ST interventions by the VSLY specific to the patient\'s country, age and year of operation.

The mathematical details of the derivation of the conversion of DALYs into country-specific VSLY are shown in the online [supplementary material](#SM1){ref-type="supplementary-material"}.
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Results {#s3}
=======

A total of 548 233 patients from 84 countries were included in the database. In total, 4113 patients were excluded from the economic analysis because of lack of GNI per capita data in the World Bank tables. These exclusions came from 14 countries, with 1039 of these excluded patients coming from Argentina. Another 865 cases from five countries were excluded because of lack of income grouping data. With the exception of 377 patients from the Palestinian Territories, for which life table data were not available, these patients were included in the calculation of averted DALYs. The gender distribution was 62% male and 38% female. The median age at the time of operation was 2; the average was 6.07 (±8.14 SD) years; for CL this was 5.55 and for CP 6.78 years.

Each CL intervention averted 2.2 DALYs on average and each CP intervention 3.3. With 3% discounting and assuming that only 90% of the patients in the study would have been unique beneficiaries of the programme, the total averted DALYs were 1 325 678 (CP 686 577 and CL 639 102). These data are presented in [table 1](#BMJGH2016000059TB1){ref-type="table"}.

###### 

DALYs averted, total and per patient

                 Average of age at treatment (rounded)   Surgically avertable disability (DALYs) *no* discount   Surgically avertable disability (DALYs) *3%* discount   Number of patients   Average averted DALYs per patient *no* discount   Average averted DALYs per patient *3%* discount
  -------------- --------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------- ------------------------------------------------- -------------------------------------------------
  Cleft palate   6.78                                     1 596 501                                               686 577                                                207 006               7.71                                              3.32
  Cleft lip      5.55                                     1 474 927                                               639 102                                                286 064               5.16                                              2.23
  Total          6.07                                     3 071 427                                               1 325 678                                              493 070               6.23                                              2.69

DALY,disability-adjusted life year.

The economic benefit derived from these procedures was between US\$7.9 and US\$20.7 billion. Per patient, the average benefit was between US\$16 133 and US\$42 351.

The economic benefit varied with the income elasticity (IE) postulated. We first selected an IE of 0.55 for upper middle-income countries (UMICs; ascertained as reasonable for this income level),[@R25] and an IE of 1.0 for low income and lower middle-income countries (LMICs) and low-income countries (LICs; consistent with evidence that lower income populations exhibit a higher elasticity for VSL).[@R26] Using these elasticities, there was a high estimate for total economic gain of US\$20.7 billion, with an average of US\$36 897 per LIC/LMIC patient and US\$173 347 per UMIC patient. The total for LICs and LMICs was US\$17.3 billion and that for UMICs was US\$3.4 billion. These data, including the stratification of CL repair and CP repair, are presented in [table 2](#BMJGH2016000059TB2){ref-type="table"}.

###### 

Economic benefit setting IEs at 1.0/0.55 (upper bound)

                 Number of LIC and LMIC patients   Number of UMIC patients   Economic benefit LIC and LMIC IE=1.0   Economic benefit UMIC IE=0.55   Total economic gain (LIC, LMIC, UMIC) IE 1.0/0.55   Average economic gain per patient LIC and LMIC IE=1.0   Average economic gain per patient UMIC IE=0.55   Average economic gain per patient IE 1.0/0.55
  -------------- --------------------------------- ------------------------- -------------------------------------- ------------------------------- --------------------------------------------------- ------------------------------------------------------- ------------------------------------------------ -----------------------------------------------
  Cleft palate    196 283                           9265                      9 395 345 138                          1 950 757 462                   11 346 102 600                                     ** 47 866**                                             ** 210 560**                                     ** 55 199**
  Cleft lip       273 086                           10 275                   7 923 094 387                          1 436 428 296                    9 359 522 683                                      ** 29 013**                                             ** 139 794**                                     ** 33 030**
  Total           469 369                           19 540                    17 318 439 525                         3 387 185 759                   20 705 625 284                                     ** 36 897**                                             ** 173 347**                                     ** 42 351**

IE, income elasticity; LIC, low-income country; LMIC, lower income and middle-income country; UMIC, upper income and middle-income country.

We then selected a more conservative IE of 1.0 for UMICs and 1.5 for LMICs and LICs. With these elasticities, the total economic gain was the low end estimate of US\$7.9 billion, with an average of US\$12 711 per LIC/LMIC patient and US\$98 329 per UMIC patient. The total for LICs and LMICs was US\$5.97 billion, and that for UMICs was US\$1.92 billion. These data are presented in [table 3](#BMJGH2016000059TB3){ref-type="table"}.

###### 

Economic benefit setting IE at 1.5/1.0 (lower bound)

                 Number of LIC and LMIC patients   Number of UMIC patients   Economic benefit LIC and LMIC IE=1.5   Economic benefit UMIC IE=1.0   Total economic gain (LIC, LMIC, UMIC) IE 1.5/1.0   Average economic gain per patient LIC and LMIC IE=1.5   Average economic gain per patient UMIC IE=1.0   Average economic gain per patient IE 1.5/1.0
  -------------- --------------------------------- ------------------------- -------------------------------------- ------------------------------ -------------------------------------------------- ------------------------------------------------------- ----------------------------------------------- ----------------------------------------------
  Cleft palate    196 283                           9265                      3 303 594 721                          1 111 203 556                  4 414 798 277                                      **16 831**                                             ** 119 941**                                    ** 21 478**
  Cleft lip       273 086                           10 275                   2 662 446 791                          810 138 454                     3 472 585 244                                      **9749**                                               ** 78 843**                                     ** 12 255**
  Total           469 369                           19 540                    5 966 041 512                          1 921 342 009                  7 887 383 521                                      **12 711**                                             ** 98 329**                                     ** 16 133**

IE, income elasticity; LIC, low-income country; LMIC, lower income and middle-income country; UMIC, upper income and middle-income country.

Owing to the incidence perspective associated with the DALYs calculated, we did not perform economic analysis of non-discounted DALYs. However, averted DALYs calculated without discounting, and again assuming that only 90% of these patients were true beneficiaries of the programme, totalled 3 071 427 (CP 1 596 501, CL 1 474 927) and for each patient, each CL intervention averted an average of 4.8 DALYs and each CP intervention 7.3.

The averted BoD data stratified by country are presented in [table 4](#BMJGH2016000059TB4){ref-type="table"}.

###### 

Averted burden of disease by country

                            Number of patients   Sum of surgically avertable disability YLD 0% discount   Sum of surgically avertable disability YLD 3% discount
  ------------------------- -------------------- -------------------------------------------------------- --------------------------------------------------------
  Afghanistan                1621                 9247                                                     4251
  Argentina                  935                  6654                                                     2666
  Armenia                    15                   101                                                      41
  Azerbaijan                 213                  1551                                                     644
  Bangladesh                 14 763               87 899                                                   37 882
  Benin                      143                  786                                                      364
  Bhutan                     122                  737                                                      329
  Bolivia                    623                  3823                                                     1651
  Brazil                     5911                 40 121                                                   16 619
  Bulgaria                   460                  3261                                                     1331
  Burkina Faso               50                   235                                                      111
  Burundi                    283                  1162                                                     591
  Cambodia                   3221                 20 241                                                   8520
  Cameroon                   82                   413                                                      203
  Cape Verde                 6                    43                                                       19
  Chile                      1146                 8641                                                     3340
  China                      159 039              1 102 846                                                454 712
  Colombia                   757                  5290                                                     2168
  Congo DR                   681                  2733                                                     1407
  Côte D'Ivoire              96                   383                                                      202
  Djibouti                   73                   391                                                      188
  Dominican Republic         61                   380                                                      158
  East Timor                 32                   51                                                       36
  Ecuador                    940                  6696                                                     2687
  Egypt                      555                  3617                                                     1512
  El Salvador                101                  662                                                      274
  Ethiopia                   11 447               50 375                                                   24 476
  Gambia                     90                   476                                                      225
  Georgia                    174                  1197                                                     493
  Ghana                      599                  3056                                                     1435
  Guatemala                  388                  2502                                                     1040
  Guinea                     21                   84                                                       42
  Guyana                     23                   131                                                      59
  Haiti                      249                  1208                                                     572
  Honduras                   182                  1237                                                     508
  India                      190 460              1 124 245                                                502 028
  Indonesia                  17 391               103 642                                                  44 456
  Iraq                       559                  3512                                                     1529
  Jordan                     130                  914                                                      369
  Kazakhstan                 173                  1099                                                     476
  Kenya                      2759                 13 637                                                   6454
  Lao PDR                    770                  4112                                                     1850
  Liberia                    185                  923                                                      435
  Madagascar                 23                   122                                                      55
  Malawi                     176                  785                                                      385
  Malaysia                   12                   75                                                       32
  Mali                       332                  1564                                                     760
  Mauritania                 97                   537                                                      245
  Mexico                     5089                 35 455                                                   14 078
  Moldova                    25                   177                                                      77
  Mongolia                   151                  954                                                      411
  Morocco                    37                   236                                                      102
  Mozambique                 82                   310                                                      165
  Myanmar                    295                  1695                                                     753
  Nepal                      8123                 47 536                                                   21 044
  Nicaragua                  257                  1751                                                     724
  Niger                      137                  664                                                      309
  Nigeria                    5036                 21 099                                                   10 866
  Pakistan                   20 827               127 564                                                  55 850
  Palestinian Territories    339                 --                                                       --
  Panama                     17                   126                                                      50
  Peru                       2950                 20 329                                                   8335
  Philippines                13 965               83 676                                                   36 423
  Russian Federation         2415                 15 960                                                   6934
  Rwanda                     228                  1013                                                     489
  Senegal                    182                  965                                                      441
  Sierra Leone               86                   336                                                      180
  Somalia                    350                  1555                                                     758
  South Africa               23                   107                                                      53
  South Sudan                41                   152                                                      79
  Sri Lanka                  1450                 10 456                                                   4251
  Sudan                      38                   159                                                      78
  Tajikistan                 37                   237                                                      104
  Tanzania                   1818                 8291                                                     4001
  Thailand                   1287                 8798                                                     3596
  Togo                       69                   351                                                      170
  Uganda                     3493                 16 829                                                   8201
  Ukraine                    340                  2200                                                     946
  Uzbekistan                 485                  3300                                                     1392
  Venezuela                  316                  2171                                                     886
  Viet Nam                   3797                 26 865                                                   10 788
  Yemen                      338                  1748                                                     797
  Zambia                     875                  3858                                                     1966
  Zimbabwe                   246                  1113                                                     564
  Grand Total                493 410              3 071 427                                                1 325 678

YLD, years lost to disability.

Discussion {#s4}
==========

Using the economic concept of the VSL to convert clinical benefit to economic gain, we found a total benefit from a surgical programme in developing countries that addressed CL and palate over an 11-year period to be at least US\$7.9 billion, up to US\$20.7 billion. For CL, this was an average of between US\$12 255 and US\$33 030 per patient over their lifetimes; for CP, it ranged between US\$21 478 and US\$55 199. Our per capita estimates are lower than other studies that have used VSL methodology ([table 5](#BMJGH2016000059TB5){ref-type="table"}).

###### 

Comparison of economic estimates of cleft lip and palate care using VSL

                        Cleft lip   Cleft palate             
  --------------------- ----------- -------------- --------- ---------
  Aggregate (current)   12 255       33 030        21 478    55 199
  Nepal (current)        2094        10 904         3113      16 062
  Corlew 2009 Nepal     56 919      143 363        152 372   375 412
  SSA (current)          2874        12 535         5058      20 799
  Alkire 2011 SSA       89 016      160 361        341 586   614 849
  Ecuador (current)      21 721      51 514         31 559    74 932
  Hughes 2012 Ecuador   52 967      141 736        145 803   390 153

VSL, value of a statistical life. SSA, sub-Saharan Africa

The human capital approach generally yields lower estimates,[@R6] [@R8] [@R27] though the previous evaluation of the current data using that approach found a *higher* upper bound when calculating with no discounting or age weighting and using the DWs from the GBD study rather than an effectiveness factor for the calculation of DALYs with the intervention.[@R17] This study makes an effort to apply the most appropriate IE-VSL estimate supported by the literature to each country, which yields lower VSL estimates for LMICs, which comprised the majority of the patients. Alkire *et al*[@R6] did not use country-specific IE-VSLs, which resulted in a uniformly higher VSL estimate than is seen in this study. Hughes *et al*[@R27] did so, but that study involved only one country (Ecuador). The Corlew study also involved only one country (Nepal) and used a VSL from Indian research for the VSL.[@R8]

This study uses a quite conservative effectiveness factor to attempt to avoid overestimating the value of the interventions. It is quite possible that this factor could in reality be significantly higher, especially in higher income countries. It is possible that as the per capita income increases, factors such as nutrition, dental care and oral hygiene, hospital conditions, available follow-up care, ancillary services such as speech, orthodontic care, etc, might more commonly accompany the operative repair, all resulting in an ultimate outcome much better than ascribed through Effectiveness Factors (EFs) of 0.5 for CP and 0.8 for CL.

More conservative estimates of the EF would be considered unlikely, but nevertheless can be examined from the perspective of sensitivity analysis for this study. This is addressed below.

When the data from this study are stratified into LMIC and UMIC, the differences between this study and the others are diminished for the UMIC countries and slightly accentuated for the LMICs ([table 6](#BMJGH2016000059TB6){ref-type="table"}).

###### 

Comparison of LMIC, UMIC and combined economic estimates (US\$)

                           Cleft lip   Cleft palate   Combined CL/CP                      
  ------------------------ ----------- -------------- ---------------- --------- -------- ---------
  LIC/LMIC                 9749        29 013         16 831           47 866    12 711   36 897
  UMIC                     78 843      139 794        119 941          210 560   98 329   173 347
  Combined LIC/LMIC/UMIC   12 255      33 030         21 478           55 199    16 133   42 351

CL, cleft lip; CP, cleft palate; LIC, low-income country; LMIC, lower income and middle-income country; UMIC,upper income and middle-income country.

We postulate that our more specific application of IE data, coupled with our appropriate use of discounting of the incidence-based DALYs calculated, yields a closer approximation of economic benefit than previous methods.

As part of the LCoGS work, Alkire *et al* examined the global macroeconomic impact of the surgical BoD using two economic approaches. These approaches, the value of lost output (VLO) and VLW, attempt to estimate the macroeconomic consequences of disease from different perspectives, but only the latter encompasses the total value of economic welfare losses.[@R10]

The VLO approach uses the WHO EPIC model,[@R28] [@R29] which models how mortality due to a particular disease process affects the labour force and capital stock of a country, thereby affecting its GDP. In this study, mortality is not considered; rather, how society values the loss of health, measured in DALYs, is the metric of interest. There are no data currently available regarding the correlation between CL/CP and participation in the labour force. While a correlation between CL/CP and participation in the labour force is intuitive, and the implication of this paper and others[@R6] [@R8] [@R27] is that such is true, it is unknown what that relationship is. Therefore, attempting to fit the VLO model to the current data was deemed to be of insufficient reliability and was not done.

The VLW approach, however, is more appropriate for assessing the total value of the economic gain provided by this vertical programme. By comparison, the human capital approach described above is quite feasible, yet does not account for all the potential losses associated with CL/CP, suffers from an unclear economic meaning given that unemployment is rarely accounted for, and per capita measures of economic output (GDP per capita, GNI per capita) do not claim to be one-to-one estimates of aggregate individual economic productivity.

The number of DALYs averted, over 1.3 million when discounted at 3%, is indicative of real and sustained value in the health of the populations affected by this surgical programme. The total for CL and CP each is similar, despite the greater number of CLs in the study. This probably reflects a number of factors: parents may not bring the children with CP in for care, some of the surgeons may not repair palates or may be limited in their capacity to do so, and there may be an unknown mortality of patients with palate precluding their presentation for care.[@R30]

The median age of 2 indicates that most patients are receiving care at close to the optimal age; the much higher average of 6.07 is skewed by the number of patients presenting in adulthood, much older than would allow them a more ideal benefit from repair. It is reasonable to speculate that many of these adult patients were denied schooling on par with their counterparts, and consequently their economic benefit, even from their age of repair, may be less than that gained by people treated in infancy.

The economic benefit realised is expectedly substantial, given that this study examines a programme that can provide lifetime resolution of a significant defect. While it would be optimal for these patients to receive further episodic care in order to improve their results further, there is no need for ongoing or maintenance care in order to continue the benefits conferred by the original operation. It is completely intuitive that returning these patients to the possibility of gainful employment and removing the need for caregiving that can be associated with these deformities could provide a major economic boost to society.

Given the relationship between income and VSL, it is expected that per capita UMIC benefit would be substantially greater than that seen in LMICs. On a per patient basis, this is indeed true ([table 2](#BMJGH2016000059TB2){ref-type="table"}). The sum, though, reflects the markedly greater work carried out in LMICs during the years of this study. ST is designed and intended to increase access to surgical care where it is lacking, which is largely in LMICs.

The cost of this programme overall was about US\$197 million (Personal communication with Mackinnon Engen, Smile Train, 2015). While it is impossible to speculate how many of these patients might have been cared for in the absence of the programme, our estimate of 10% is quite reasonable. The true counterfactual is unknown, so a 'return on investment' (ROI) of between 40 and 105 dollars per dollar spent, as well as a cost benefit ratio of US\$149 per DALY averted, is only speculation.

The problem of poor access to surgical care is arguably one of the greatest issues facing the global health community.[@R1] This study indicates that the value of a vertical programme providing surgical care for one disease, orofacial clefting, can be substantial. Such a programme does not, however, delve into the complex task of strengthening health systems and infrastructure development that is necessary to improve surgical care. Infrastructure, training surgeons, anaesthesia providers, nurses and others integral to the provision of surgical care, governmental and NGO commitment and support, and cultural acceptance are all necessary for the scaling of benefits seen in this study. There will undoubtedly continue to be the yin and yang of more thorough addressing of smaller pieces of the surgical pie as seen here as opposed to addressing of the greater surgical need.

Limitations {#s4a}
-----------

Mortality due to cleft lip and palate (CLP) was not considered in this study, despite the presence of a small but unknown mortality risk associated with CP. Christensen and colleagues found increased mortality (mortality ratio 1.4 for males and 1.8 for females) in patients with CLP up to age 55, with the increase essentially exclusively due to patients with CLP as opposed to CL alone. They also found that this increased risk was equivalent over the time intervals of age 0--1, 2--17 and 18--55. This was multifactorial, although suicide was a significant factor.[@R31] Carlson and colleagues, in a literature meta-analysis found an increase in mortality through the first year of life. This was substantially greater for people with associated anomalies (OR 9.47) than for isolated CLP (OR 2.07).[@R32] Both of these studies addressed only patients from high-income countries, and it is quite reasonable to consider that mortality might be higher in the developing country population largely addressed in this study. Dai *et al*[@R33] reported a neonatal mortality of over 6% in patients with CL±CP without associated anomalies in a developing country setting, consistent with this supposition. In a similar setting, Wilson and Hodges extrapolated that as many as 91% of patients with CP may die prior to reasonable presentation for repair.[@R30]

It is apparent that any consideration of mortality (YLLs in addition to YLDs in the calculation of DALYs) would increase the calculated value of the interventions in this study.

By necessity, this study has invoked a number of assumptions, starting with those of the GBD study in the development of DWs. The DWs from the 2004 study were revised from those of the original study and included CIs, but for CP and CL included only a single, composite DW including all people with a cleft, including those who had been treated.[@R34] Since this study specifically addresses only people who had had no treatment, these values were not appropriate for this study. The original GBD study published treated and untreated DWs, which were used in the current work. By postulating that an appropriate level of uncertainty for these DWs was an SD of 0.25 of the value, calculated as ((value)±1.96×0.25(value)), we could determine an estimate of the uncertainty associated with this aspect of our estimates. These calculations are summarised in [table 7](#BMJGH2016000059TB7){ref-type="table"}. They indicate that with the lower end of the DW value, the programme contributed between \$3.7 and \$10.0 billion to the economy, depending on the IEs considered. At that lower bound of the DWs, the speculated cost per DALY averted was \$291, and the ROI was between 19 and 51. At the higher end, these numbers were US\$11.8--US\$30.8 billion, the cost per DALY averted \$100, and the ROI between 60 and 157.

###### 

Sensitivity analysis of DWs

                                        Total economic gain IE 1.5/1.0   Total economic gain IE 1.0/0.55   Sum of DALYs averted 3% discount   \$/DALY averted   ROI IE 1.5/1.0   ROI IE 1.0/0.55
  ------------------------------------- -------------------------------- --------------------------------- ---------------------------------- ----------------- ---------------- -----------------
  DW lower bound (CP 0.118, CL 0.050)    3 744 122 425                    10 081 309 630                   676 791                            291               19               51
  **DW (CP 0.231, CL 0.098)**           ** 7** **887** **383 521**       ** 20 705 625** **284**           ** 1 325 678**                     ** 149**          **40**           ** 105**
  DW upper bound (CP 0.344, CL 0.146)    11 758 779 624                   30 841 548 039                   1 974 565                          100               60               157

CL, cleft lip; CP, cleft palate; DALY, disability-adjusted life year; DW, disability weight; IE, income elasticity; ROI, return on investment.

Values to reflect the effectiveness of the intervention (surgical repair of the cleft), here set conservatively at 0.8 and 0.5 for CL and CP, respectively, are also purely assumptions. There are no data actually quantifying what constitutes optimal rehabilitation of patients with CLP, and it would be quite difficult to apply such a determination across economic and cultural divides. Analysis of various scenarios using lower and higher EFs was performed and is summarised in [table 8](#BMJGH2016000059TB8){ref-type="table"}. A higher EF may well be more appropriate, and of course indicates even greater value to the programme. Lower ones might be argued, and while they indicate decreasing values of the programme, even at EFs of 0.2 and 0.5 (only 20% efficacy of the surgical repair of a CP and 50% for repair of CL), there is still significant value of the programme. Even at the lowest value modelled, the speculated ROI was still 22, and cost per DALY averted was 263.

###### 

Scenario analysis of effectiveness factor

                   Total economic gain IE 1.5/1.0   Total economic gain IE 1.0/0.55   Sum 3% DALYs averted   \$/DALY   ROI       
  ---------------- -------------------------------- --------------------------------- ---------------------- --------- --------- --------
  EF 0.2/0.5       4 367 139 093                    11 523 037 315                    748 964                263       58        22
  EF 0.3/0.6       5 828 471 895                    15 338 406 750                    990 300                199       78        30
  EF 0.4/0.7        7 289 804 696                    19 153 776 186                   1 231 636              160       97        37
  **EF 0.5/0.8**   ** 7 887 383 521**               ** 20 705 625 284**               **1 325 678**          **149**   **105**   **40**
  EF 0.6/0.9       10 212 470 298                   26 784 515 057                    1 714 308              115       136       52

DALY, disability-adjusted life year; IE, income elasticity; ROI, return on investment.

The IE estimates are derived from the economic literature, but also are at best estimates given the relative absence of empirical VSL studies from LMICs.

VSL can be criticised as overly hypothetical, and its determination difficult. It also is subject to cultural, economic, national, regional and possibly even religious differences. By calculating a country-specific VSL for each country represented in this study, we attempted to account for at least the national economic differences. How cultural or religious perspectives might play into how people view the value of their lives is more difficult to evaluate. We used the IE as a way to allow for how these perspectives might affect VSL.

VSL was conceived as a tool to evaluate life, with its value to be used as a whole. It was not conceived to be used with its value split into fractions of the whole in order to evaluate disability or impairment. This issue is consistent with the model of DALYs (or healthy-adjusted life years, quality-adjusted life years or other measurements of health) as opposed to using only mortality as a health measure. This extrapolation has not been subjected to the type of sociological studies conducted by Viscusi and colleagues that established the value of VSL. By applying the age weighting data in our calculation of VSLY, however, we have attempted to make this conversion valid in this study.

Ideally, the economic impact of a surgical intervention would be evaluated by a long-term field study examining the economic difference over a lifetime between individuals who had benefited from surgical care and those who had not. This option is, however, not logistically, financially or ethically feasible---hence, modelling techniques remain the mainstay.

Conclusions {#s5}
===========

This study applies a widely used economic approach to attempt to capture the societal gain provided by a large surgical intervention programme in developing countries. It demonstrates the use of VLW modelling, as applied in the LCoGS to overall surgical activity in the world, to a specific surgical problem. As opposed to extending the meaning of per capita economic output measures such as GNI per capita beyond its original intent, this methodology attempts to capture the total economic welfare gains, which include the value of good health in and of itself, associated with surgical repair of CLP. Pursuant to the overarching economic estimates of surgical care described in the LCoGS, it refines the application of VLW methodology to a single surgical intervention. Given the large economic value shown by this study in a scaled vertical surgical programme, it suggests that there is a strong economic argument for greater emphasis on the expansion of surgical care for the majority of the global population that is currently underserved.
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